Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.

Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.9%
- Check11 days agoChange DetectedThe page has removed a citation related to the American Society of Clinical Oncology's guidelines for systemic therapy in stage IV non-small-cell lung cancer.SummaryDifference0.2%
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page has removed a detailed citation of a clinical trial related to Cabozantinib and Sunitinib, which may affect the availability of important information regarding treatment options for metastatic renal cell carcinoma.SummaryDifference0.4%
- Check32 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check39 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a clinical trial for cabozantinib in non-small cell lung cancer, while adding a new version revision and a brief mention of the CRETA trial.SummaryDifference24%
- Check54 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.